Alphamab Oncology Appoints Han Jing as Chief Commercial Officer

SUZHOU, Nov. 2, 2021 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced the appointment of Mr. Han Jing as Chief Commercial Officer, responsible for the company's commercialization activities, reporting to Dr. Xu Ting, Chairman and President of the Company.

Mr. Han Jing

Mr. Han Jing has been deeply engaged in the Chinese pharmaceutical market for over two decades. He has successively served at globally renowned multinational pharmaceutical companies, including MSD, Boehringer Ingelheim, AstraZeneca, Bayer, and Roche, as well as Chinese innovative biopharmaceutical companies such as Junshi Biosciences, accumulating extensive experience in building and leading commercialization teams, as well as formulating and executing commercial strategies. Prior to joining Alphamab Oncology, Mr. Han served as Senior Vice President at Genor Biopharma, where he was responsible for establishing the marketing team and overseeing all pre-launch commercialization activities.

Dr. Xu Ting, Chairman and President of Alphamab Oncology, stated: “We welcome Mr. Han Jing to Alphamab Oncology. Since our founding, we have been committed to building a fully integrated, internationally competitive innovative biopharmaceutical company. The Company is poised to launch its first marketed product, and our core product, KN046, is also scheduled to submit a marketing application next year. Mr. Han brings extensive commercialization experience from both multinational and domestic pharmaceutical companies, having repeatedly led teams to successfully bring outstanding innovative drugs to market, thereby benefiting a wide patient population. We believe his appointment will accelerate the commercialization of KN046 and our future blockbuster products.”

Mr. Han Jing, Chief Commercial Officer of Alphamab Oncology, stated: “In the rapidly evolving wave of biopharmaceutical innovation in China, Alphamab Oncology is undoubtedly a shining star. Under the leadership of Chairman Xu Ting, the company has pioneered various multi-specific antibody development platforms, integrating exceptional R&D and manufacturing capabilities. I strongly endorse the mission of the Chairman and the company to ‘make cancer a controllable and treatable disease,’ as well as the strategy of ‘being rooted in China and looking to the world.’ I am confident that in the near future, Alphamab Oncology will deliver numerous ‘first-in-class’ and ‘best-in-class’ products to benefit patients both domestically and internationally. I will work hand in hand with my colleagues to strive for this goal!”

Mr. Han Jing graduated from the Department of Clinical Medicine at Shanghai Second Medical University in 1996 and began his career as a general surgeon. In 1998, he chose to join MSD, embarking on a career in the pharmaceutical industry that has spanned over two decades. In 2018, Mr. Han Jing earned an EMBA degree from China Europe International Business School (CEIBS).

About Alphamab Oncology

Alphamab Oncology focuses on the research and development, manufacturing, and commercialization of innovative anti-tumor drugs. On December 12, 2019, the Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited, Stock Code: 9966.

Alphamab Oncology possesses an integrated discovery, R&D, and manufacturing platform spanning the entire value chain in bispecific antibodies and protein engineering. The company’s product pipeline comprises 15 highly differentiated, proprietary anti-tumor candidate drugs primarily based on bispecific antibodies, along with one multi-functional antibody for COVID-19. Of these, four products are currently in Phase I–III clinical trials in China, the United States, Japan, and Australia. The marketing authorization application for envafolimab injection (KN035) has been formally accepted by the National Medical Products Administration (NMPA) and granted priority review.

The Company possesses multiple proprietary technology platforms, including those for heterodimers and mix-and-match antibodies, large-scale manufacturing capabilities compliant with cGMP standards in China, the United States, and the European Union, and a comprehensive quality system that has successfully passed multiple audits, including those conducted by EU Qualified Persons (QPs). The Company is committed to building an internationally leading, multi-dimensional platform for drug development and commercialization, focusing on novel multifunctional biologics to benefit patients in China and worldwide.

Welcome to the company website:www.alphamabonc.com